JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

Search

Innoviva Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

17.87 1.82

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

17.45

Max

17.92

Pagrindiniai rodikliai

By Trading Economics

Pajamos

110M

64M

Pardavimai

12M

100M

P/E

Sektoriaus vid.

31.088

37.003

Pelno marža

63.508

Darbuotojai

127

EBITDA

111M

84M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+116.28% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-50M

1.1B

Ankstesnė atidarymo kaina

16.05

Ankstesnė uždarymo kaina

17.87

Naujienos nuotaikos

By Acuity

42%

58%

157 / 373 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Innoviva Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-29 23:28; UTC

Karštos akcijos

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

2025-10-29 23:07; UTC

Uždarbis

Prudential PLC 3Q New Business Profit Up 13%

2025-10-30 00:00; UTC

Uždarbis

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

2025-10-30 00:00; UTC

Uždarbis

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

2025-10-30 00:00; UTC

Uždarbis

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

2025-10-29 23:46; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

2025-10-29 23:40; UTC

Uždarbis

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

2025-10-29 23:38; UTC

Rinkos pokalbiai

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

2025-10-29 23:25; UTC

Uždarbis

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

2025-10-29 22:51; UTC

Uždarbis

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

2025-10-29 22:45; UTC

Uždarbis

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

2025-10-29 22:41; UTC

Uždarbis

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

2025-10-29 22:41; UTC

Uždarbis

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

2025-10-29 22:09; UTC

Uždarbis

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

2025-10-29 22:08; UTC

Rinkos pokalbiai
Uždarbis

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

2025-10-29 21:58; UTC

Uždarbis

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

2025-10-29 21:58; UTC

Uždarbis

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

2025-10-29 21:57; UTC

Uždarbis

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

2025-10-29 21:54; UTC

Uždarbis

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

2025-10-29 21:46; UTC

Uždarbis

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

2025-10-29 21:43; UTC

Uždarbis

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

2025-10-29 21:43; UTC

Uždarbis

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

2025-10-29 21:42; UTC

Uždarbis

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

2025-10-29 21:42; UTC

Uždarbis

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

2025-10-29 21:41; UTC

Uždarbis

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

2025-10-29 21:41; UTC

Uždarbis

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

2025-10-29 21:41; UTC

Uždarbis

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

2025-10-29 21:41; UTC

Uždarbis

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

2025-10-29 21:40; UTC

Uždarbis

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

2025-10-29 21:39; UTC

Uždarbis

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Akcijų palyginimas

Kainos pokytis

Innoviva Inc Prognozė

Kainos tikslas

By TipRanks

116.28% į viršų

12 mėnesių prognozė

Vidutinis 38 USD  116.28%

Aukščiausias 55 USD

Žemiausias 17 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Innoviva Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

4 ratings

3

Pirkti

0

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

18.57 / 18.75Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Neutral Evidence

Rinkos nuotaikos

By Acuity

157 / 373 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat